Abstract
Although the µ opioid receptor (MOR) was pharmacologically and biochemically identified in binding studies forty years ago, its structure, function, and true complexity only have emerged after its cloning in 1993. Continuous efforts from many laboratories have greatly advanced our understanding of MORs, ranging from their anatomic distribution to cellular and molecular mechanisms, and from cell lines to in vivo systems. The MOR is recognized as the main target for effective pain relief, but its involvement in many other physiological functions has also been recognized. This review provides a synopsis on the history of research on MORs and ligands acting at the MOR with the focus on their clinical and potential use as therapeutic drugs, or as valuable research tools. Since the elucidation of the chemical structure of morphine and the characterization of endogenous opioid peptides, research has stimulated the development of new generations of MOR ligands with distinct pharmacological profiles (agonist, antagonist, mixed agonist/antagonist and partial agonist) or site of action (central/peripheral). Discovery of therapeutically useful morphine-like drugs and innovative drugs with new scaffolds, with several outstanding representatives, is discussed. Extensive efforts on modifications of endogenous peptides to attain stable and MOR selective analogs are overviewed with stimulating results for the development of peptide-based pharmaceuticals. With pharmacophore modeling as an important tool in drug discovery, application of modern computational methodologies for the development of morphinans as new MOR ligands is described. Moreover, the crystal structure of the MOR available today will enable the application of structurebased approaches to design better drugs for the management of pain, addiction and other human diseases, where MORs play a key role.
Keywords: µ Opioid receptor, pain, agonist, antagonist, morphine, morphinans, pharmacophore.
Current Pharmaceutical Design
Title:The µ Opioid Receptor and Ligands Acting at the µ Opioid Receptor, as Therapeutics and Potential Therapeutics
Volume: 19 Issue: 42
Author(s): Mariana Spetea, Muhammad Faheem Asim, Gerhard Wolber and Helmut Schmidhammer
Affiliation:
Keywords: µ Opioid receptor, pain, agonist, antagonist, morphine, morphinans, pharmacophore.
Abstract: Although the µ opioid receptor (MOR) was pharmacologically and biochemically identified in binding studies forty years ago, its structure, function, and true complexity only have emerged after its cloning in 1993. Continuous efforts from many laboratories have greatly advanced our understanding of MORs, ranging from their anatomic distribution to cellular and molecular mechanisms, and from cell lines to in vivo systems. The MOR is recognized as the main target for effective pain relief, but its involvement in many other physiological functions has also been recognized. This review provides a synopsis on the history of research on MORs and ligands acting at the MOR with the focus on their clinical and potential use as therapeutic drugs, or as valuable research tools. Since the elucidation of the chemical structure of morphine and the characterization of endogenous opioid peptides, research has stimulated the development of new generations of MOR ligands with distinct pharmacological profiles (agonist, antagonist, mixed agonist/antagonist and partial agonist) or site of action (central/peripheral). Discovery of therapeutically useful morphine-like drugs and innovative drugs with new scaffolds, with several outstanding representatives, is discussed. Extensive efforts on modifications of endogenous peptides to attain stable and MOR selective analogs are overviewed with stimulating results for the development of peptide-based pharmaceuticals. With pharmacophore modeling as an important tool in drug discovery, application of modern computational methodologies for the development of morphinans as new MOR ligands is described. Moreover, the crystal structure of the MOR available today will enable the application of structurebased approaches to design better drugs for the management of pain, addiction and other human diseases, where MORs play a key role.
Export Options
About this article
Cite this article as:
Spetea Mariana, Asim Faheem Muhammad, Wolber Gerhard and Schmidhammer Helmut, The µ Opioid Receptor and Ligands Acting at the µ Opioid Receptor, as Therapeutics and Potential Therapeutics, Current Pharmaceutical Design 2013; 19 (42) . https://dx.doi.org/10.2174/13816128113199990362
DOI https://dx.doi.org/10.2174/13816128113199990362 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A New Alzheimers Disease Interventive Strategy: GLP-1
Current Drug Targets Commentary (Research Highlights: Wnt-Signalling: A New Direction for Alzheimer Disease?)
CNS & Neurological Disorders - Drug Targets Parkinson’s Disease and Alpha-Synucleinopathies: from Arising Pathways to Therapeutic Challenge
Central Nervous System Agents in Medicinal Chemistry Who Should Receive Low-Dose Aspirin for Pre-eclampsia Prevention? Sorting through the Meta-Analyses
Current Women`s Health Reviews DNA Minor Groove Binders: an Overview on Molecular Modeling and QSAR Approaches
Current Medicinal Chemistry Lymphoid-Specific Tyrosine Phosphatase (Lyp): A Potential Drug Target For Treatment of Autoimmune Diseases
Current Drug Targets New Trends in Liposome-based Drug Delivery in Colorectal Cancer
Mini-Reviews in Medicinal Chemistry Editorial [Hot topic: Transgenic Animal Models of Neurodegenerative Diseases (Guest Editor: Stephen D. Skaper)]
CNS & Neurological Disorders - Drug Targets The Effects of CCRC on Cognition and Brain Activity in aMCI Patients: A Pilot Placebo Controlled BOLD fMRI Study
Current Alzheimer Research Genetics of Anxiety Disorders - Status Quo and Quo Vadis
Current Pharmaceutical Design Could Sigma Receptor Ligands be a Treatment for Methamphetamine Addiction?
Current Drug Abuse Reviews Development and Validation of a Fluorescence-Based HTS Assay for the Identification of P/Q-Type Calcium Channel Blockers
Combinatorial Chemistry & High Throughput Screening Biosynthetic Pathways of Bioactive N-Acylethanolamines in Brain
CNS & Neurological Disorders - Drug Targets Autoimmune Disorders during Pregnancy: Effects of Biomarkers on Maternal Serum Screening and Course of Disease
Current Women`s Health Reviews Natural Polyphenols in the Treatment of Alzheimer’s Disease
Current Drug Targets SLC1 Glutamate Transporters and Diseases: Psychiatric Diseases and Pathological Pain
Current Molecular Pharmacology Why are Antidepressant Drugs Effective Smoking Cessation Aids?
Current Neuropharmacology Industrial Production of the Cell Protectant Ectoine: Protection Mechanisms, Processes, and Products
Current Biotechnology In Vivo Application of beta Amyloid Oligomers: A Simple Tool to Evaluate Mechanisms of Action and New Therapeutic Approaches
Current Pharmaceutical Design A Comparative Study of Short Term Efficacy of Aripiprazole and Risperidone in Schizophrenia
Current Neuropharmacology